Kathleen Large

An industry veteran of large, mid-size, and small biopharma companies with 20+ years of experience in clinical development and operations for oncology, immuno-oncology, and cell therapy agents. Expertise in global clinical programs at Eli Lilly, Takeda, Epizyme, and, most recently, Trillium Therapeutics, which was acquired by Pfizer for its CD47 program.